Author:
Mattner Frauke,Schulz-Stübner Sebastian
Publisher
Springer Berlin Heidelberg
Reference27 articles.
1. Anonymous (2009) Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 58:256–260
2. Bassetti M, Echols R, Matsunaga Y et al (2021) Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis 21(2):226–240
3. Bush K, Jacoby GA, Medeiros AA (1995) A functional classification scheme for beta-laktamases and its correlation with molecular structure. Antimicrob Agents Chemother 39:1211–1233
4. Fritzwanker M, Imirzallioglu C, Herold S et al (2018) Therapieoptionen bei Carbapenem-resistenten gramnegativen Erregern. Dtsch Arztebl Int 115:345–352
5. Grundmann H, Barwolff S, Tami A (2005) How many infections are caused by patient-to-patient transmission in intensive care units? Crit Care Med 33:946–951